Can crizotinib be taken only for advanced lung cancer?

Crizotinib is not limited to patients with advanced lung cancer, but it is mainly used to treat patients with non-small cell lung cancer (NSCLC) who carry specific gene mutations. These mutations usually include anaplastic lymphoma kinase (ALK) positivity and ROS1 positivity.

Crizotinib is the world's first targeted drug approved for the treatment of ALKpositive NSCLC. For such patients, regardless of the stage of their cancer (early, locally advanced, or metastatic), crizotinib may be an effective treatment option as long as they carry ALK gene fusions or mutations.

In addition to ALKpositive NSCLC , crizotinib is also suitable for the treatment of ROS1positive NSCLC patients. These patients may also benefit from treatment with crizotinib.

In patients with advanced lung cancer, crizotinib is often used as a first-line or subsequent treatment option, especially for those who cannot tolerate or fail chemotherapy. It can help prolong patient survival and improve quality of life.

Although crizotinib is mainly used to treat advanced lung cancer, for some patients with early or locally advanced ALK-positive or ROS1-positive NSCLC, crizotinib may also be considered as part of adjuvant or neoadjuvant treatment if local treatments such as surgery or radiotherapy are not suitable or ineffective. However, this requires physicians to make individualized decisions based on the patient's specific circumstances.

Before using crizotinib, patients must undergo genetic testing to confirm whether there are mutations in sensitive genes such as ALK or ROS1. This is a critical step in determining whether a patient is a candidate for crizotinib.

Crizotinib may cause a series of side effects, such as visual impairment, digestive system reactions (nausea, vomiting, diarrhea, etc.), elevated liver enzymes, etc. Therefore, the patient's body response needs to be closely monitored during use and side effects must be dealt with in a timely manner.